Syntara Ltd
SNT
Company Profile
Business description
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.
Contact
20 Rodborough Road
Unit 2
Frenchs Forest
SydneyNSW2086
AUST: +61 287601480
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2025
Employees
93
Syntara Ltd News & Analysis
stocks
CSL remains favourite, but biotech field broadening
The biotech giant has jumped 22pc a year for the past decade but new players are emerging.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,430.30 | 113.60 | 1.37% |
| CAC 40 | 7,274.48 | 19.89 | -0.27% |
| DAX 40 | 19,884.75 | 85.11 | -0.43% |
| Dow JONES (US) | 42,840.26 | 498.02 | 1.18% |
| FTSE 100 | 8,084.61 | 20.71 | -0.26% |
| HKSE | 19,810.08 | 89.38 | 0.45% |
| NASDAQ | 19,572.60 | 199.83 | 1.03% |
| Nikkei 225 | 39,043.59 | 341.69 | 0.88% |
| NZX 50 Index | 12,925.71 | 21.60 | 0.17% |
| S&P 500 | 5,930.85 | 63.77 | 1.09% |
| S&P/ASX 200 | 8,179.00 | 112.00 | 1.39% |
| SSE Composite Index | 3,378.83 | 10.76 | 0.32% |